Jifang Sheng

TL;DR: Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China; Department of Infectiously Diseases, Center for Liver Diseases, Peking University First Hospital, Beijing; The Institute of Translational Hepatology, 302 Hospital of PLA, P Beijing, China.

TL;DR: For patients who achieve virological suppression with ETV, switching to a finite course of peginterferon alfa-2a significantly increases rates of HBeAg seroconversion and HBsAg loss.

TL;DR: Baseline anti-HBc titre is a useful predictor of Peg-IFN and NUC therapy efficacy in HBeAg-positive CHB patients, which could be used for optimising the antiviral therapy of CHB.

TL;DR: Patients with baseline qAnti-HBc levels ≥30,000 IU/mL had significantly higher response rates, more HBV DNA suppression, and better hepatitis control in PEG-IFN treatment.

TL;DR: In a randomized controlled trial of patients with chronic HBV infection, entecavir therapy is associated with a low rate of adverse events over 10 years of follow up and participants in a China cohort who maintained a virologic response had a reduced risk of HBV-related outcome events including hepatocellular carcinoma.